Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity, and inflammatory biomarkers in pre-diabetes: a randomised placebo-controlled clinical trial

C.V. Hall,J.L. Twelves,M. Saxena,L Scapozza,T. Gurry

DOI: https://doi.org/10.1101/2024.01.09.24301052

2024-01-11

Abstract:Prebiotic fibre represents a promising and efficacious treatment to manage pre-diabetes, acting via complementary pathways involving the gut microbiome and viscosity-related properties. In this study, we evaluated the effect of using a diverse prebiotic fibre supplement on glycaemic, lipid, and inflammatory biomarkers in patients with pre-diabetes. Sixty-six patients diagnosed with pre-diabetes (yet not receiving glucose-lowering medications) were randomised into treatment (n = 33) and placebo (n = 33) interventions. Participants in the treatment arm consumed 20g per day of a diverse prebiotic fibre supplement and participants in the placebo arm consumed 2g per day of cellulose for 24 weeks. A total of 51 and 48 participants completed the week 16 and week 24 visits, respectively. The intervention was well-tolerated, with a high average adherence rate across groups. Our results extend upon previous work, showing a significant change in glycated haemoglobin (HbA1c) in the treatment group, but only in participants with lower baseline HbA1c levels (<6% HbA1c). Within the whole cohort, we showed significant improvements in insulin sensitivity, fasting plasma insulin, and C-reactive protein in the treatment group compared with the placebo. We did not observe any between-group differences in lipid profiles or other inflammatory cytokines. Together, our results show support for the beneficial effects of a diverse prebiotic fibre supplement on physiologically relevant biomarkers in pre-diabetes.

Endocrinology (including Diabetes Mellitus and Metabolic Disease)

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effect of using diverse prebiotic fiber supplements on glycated hemoglobin (HbA1c), insulin sensitivity and inflammation markers in patients with prediabetes. Specifically, the study aims to evaluate whether such supplements can improve the metabolic, lipid and inflammation biomarkers in patients with prediabetes. In addition, the study also explores how these effects are manifested in subgroups with different baseline HbA1c levels, especially for participants with a lower baseline HbA1c level (<6%).

The study evaluates this issue through a randomized, placebo - controlled clinical trial. The trial is rigorously designed, using a parallel - arm, individually randomized, single - blind method and has been approved by the ethics committee. The primary endpoint of the study is the change in HbA1c at 16 weeks, and the secondary endpoints include the change in HbA1c at 24 weeks, the change in insulin sensitivity, the change in fasting plasma insulin level, the change in lipid profile, the change in inflammation markers, and the change in diastolic and systolic blood pressure. Through the measurement of these indicators, the researchers hope to understand the specific effects of diverse prebiotic fiber supplements on physiologically relevant biomarkers in patients with prediabetes, thereby providing new intervention means for preventing the progression of prediabetes to type 2 diabetes.